ZFHX3 and non-small cell lung carcinoma: found that ZFHX3 mutations were closely related to longer overall survival in NSCLC patients treated with ICBs and suggested that ZFHX3 mutations could be used as a novel predictive marker in guiding NSCLC ICB treatment (37).